Speculation of AstraZeneca/Starpharma indication - Could it be AZD0466, page-13

I'm wondering does the statement below from the annual review Biotechcatalyst found indicate Astrazeneca is trying to create its on Dendrimer technology to use instead of the Starpharma technology.

I'm not sure because the jargon gets a bit lost on me i'm afraid however I would 100% expect them to try to make their own version. Possibly someone else could inform us if we are at risk of being made redundant in the near future. If they are trying to create their own dendrimer technology to use then I wouldn't expect many deals in the near future.


https://www.astrazeneca.com/content/dam/az/Our-Science/IMED-Biotech-Unit/IMED_Annual Review_2016.pdf

"Pharmaceutical Sciences has also implemented the innovative modelling efforts to help in the design phase and built an internal capability to produce prototype nanoparticles, enabling rapid exploration in internal projects. In addition, the team has been driving science through collaboration across IMED, to further understand the technology and translational elements of nanomedicines including potential impact in combination therapy."